These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 22123395)
1. Antibodies against a synthetic peptide designed to mimic a surface area of the H chain of botulinum neurotoxin A. Atassi MZ; Dolimbek BZ; Steward LE; Aoki KR Immunol Lett; 2012 Feb; 142(1-2):20-7. PubMed ID: 22123395 [TBL] [Abstract][Full Text] [Related]
2. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Dolimbek BZ; Aoki KR; Steward LE; Jankovic J; Atassi MZ Mol Immunol; 2007 Feb; 44(5):1029-41. PubMed ID: 16647121 [TBL] [Abstract][Full Text] [Related]
3. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. Atassi MZ; Jankovic J; Steward LE; Aoki KR; Dolimbek BZ Immunobiology; 2012 Jan; 217(1):17-27. PubMed ID: 21962573 [TBL] [Abstract][Full Text] [Related]
4. Regions of recognition by blocking antibodies on the light chain of botulinum neurotoxin A: antigenic structure of the entire toxin. Dolimbek BZ; Steward LE; Aoki KR; Atassi MZ Immunobiology; 2011 Jun; 216(6):698-706. PubMed ID: 21183243 [TBL] [Abstract][Full Text] [Related]
5. Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains. Dolimbek GS; Dolimbek BZ; Aoki KR; Atassi MZ Immunol Invest; 2005; 34(2):119-42. PubMed ID: 15921155 [TBL] [Abstract][Full Text] [Related]
6. Antibody and T cell recognition of the light chain of botulinum neurotoxin A in two high-responder mouse strains. Atassi MZ; Oshima M; Dolimbek BZ; Aoki KR Immunobiology; 2012 Jan; 217(1):1-7. PubMed ID: 22015045 [TBL] [Abstract][Full Text] [Related]
7. Reduction of established antibody responses against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol peptide conjugates. Atassi MZ; Naqvi M; Dolimbek BZ; Aoki KR J Neuroimmunol; 2014 Jul; 272(1-2):29-34. PubMed ID: 24841626 [TBL] [Abstract][Full Text] [Related]
8. Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A. Atassi MZ; Dolimbek GS; Deitiker PR; Aoki KR; Dolimbek BZ Mol Immunol; 2005 Aug; 42(12):1509-20. PubMed ID: 15950744 [TBL] [Abstract][Full Text] [Related]
9. Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on the Clostridium botulinum neurotoxin type A. Wu HC; Yeh CT; Huang YL; Tarn LJ; Lung CC Appl Environ Microbiol; 2001 Jul; 67(7):3201-7. PubMed ID: 11425742 [TBL] [Abstract][Full Text] [Related]
10. Location of the synaptosome-binding regions on botulinum neurotoxin B. Dolimbek BZ; Steward LE; Aoki KR; Atassi MZ Biochemistry; 2012 Jan; 51(1):316-28. PubMed ID: 22146011 [TBL] [Abstract][Full Text] [Related]
11. Regions recognized on the light chain of botulinum neurotoxin type A by T lymphocytes of SJL and BALB/c mice primed with inactivated toxin. Oshima M; Aoki KR; Atassi MZ Immunobiology; 2014 Dec; 219(12):950-7. PubMed ID: 25151501 [TBL] [Abstract][Full Text] [Related]
12. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Atassi MZ; Dolimbek BZ; Jankovic J; Steward LE; Aoki KR Mol Immunol; 2008 Sep; 45(15):3878-88. PubMed ID: 18676021 [TBL] [Abstract][Full Text] [Related]
13. A peptide-based immunoassay for antibodies against botulinum neurotoxin A. Atassi MZ; Dolimbek BZ; Deitiker P; Jankovic J; Aoki KR J Mol Recognit; 2007; 20(1):15-21. PubMed ID: 16981247 [TBL] [Abstract][Full Text] [Related]
14. Localization of the regions on the C-terminal domain of the heavy chain of botulinum A recognized by T lymphocytes and by antibodies after immunization of mice with pentavalent toxoid. Rosenberg JS; Middlebrook JL; Atassi MZ Immunol Invest; 1997 Jun; 26(4):491-504. PubMed ID: 9246568 [TBL] [Abstract][Full Text] [Related]
15. Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A. Atassi MZ; Dolimbek BZ Protein J; 2004 Jan; 23(1):39-52. PubMed ID: 15115181 [TBL] [Abstract][Full Text] [Related]
16. Characterization of the monoclonal antibody response to botulinum neurotoxin type A in the complexed and uncomplexed forms. Zhao H; Nakamura K; Kohda T; Mukamoto M; Kozaki S Jpn J Infect Dis; 2012; 65(2):138-45. PubMed ID: 22446121 [TBL] [Abstract][Full Text] [Related]
17. Recombinant proteins that trigger production of antibodies recognizing botulinum neurotoxin while not possessing sequences of this toxin. Zdanovsky A; Zdanovskaia M Toxicon; 2013 Jun; 67():63-70. PubMed ID: 23499926 [TBL] [Abstract][Full Text] [Related]
18. Inhibition by human sera of botulinum neurotoxin-A binding to synaptosomes: a new assay for blocking and non-blocking antibodies. Maruta T; Dolimbek BZ; Aoki KR; Atassi MZ J Neurosci Methods; 2006 Mar; 151(2):90-6. PubMed ID: 16466805 [TBL] [Abstract][Full Text] [Related]
19. Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Atassi MZ; Dolimbek BZ; Jankovic J; Steward LE; Aoki KR Immunobiology; 2011 Jul; 216(7):782-92. PubMed ID: 21281977 [TBL] [Abstract][Full Text] [Related]
20. Immune recognition of BoNTs A and B: how anti-toxin antibodies that bind to the heavy chain obstruct toxin action. Atassi MZ Toxicon; 2009 Oct; 54(5):600-13. PubMed ID: 19285100 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]